Acquire the license to the best health content in the world
Contact Us

Exercise Cuts Later CV Risk in Hodgkin's Lymphoma Survivors

Vigorous exercise may lower cardiovascular risk in adult survivors of childhood Hodgkin's lymphoma

Exercise Cuts Later CV Risk in Hodgkin's Lymphoma Survivors

THURSDAY, Oct. 16, 2014 (HealthDay News) -- Exercise may lower the risk of treatment-related cardiovascular events in adult survivors of childhood Hodgkin's lymphoma, according to research published online Oct. 13 in the Journal of Clinical Oncology.

Lee W. Jones, Ph.D., of the Memorial Sloan Kettering Cancer Center in New York City, and colleagues used questionnaires to evaluate exercise behavior and occurrence of cardiovascular events in 1,187 adult survivors (median age, 31.2 years) of childhood Hodgkin's lymphoma.

The researchers found, over a median follow-up of 11.9 years (range, 1.7 years to 14.3 years), that the cumulative incidence of any cardiovascular event at 10 years was higher among cancer survivors reporting zero metabolic equivalent (MET) hours/week−1 of vigorous-intensity exercise (12.2 percent) than those reporting ≥9 MET hours/week−1 (5.2 percent). Compared with cancer survivors reporting zero MET hours/week−1, the adjusted rate ratio for any cardiovascular event was 0.87 (95 percent confidence interval [CI], 0.56 to 1.34) for those reporting three to six MET hours/week−1, 0.45 (95 percent CI, 0.26 to 0.8) for those reporting 9 to 12 MET hours/week−1, and 0.47 (95 percent CI, 0.23 to 0.95) for those reporting 15 to 21 MET hours/week−1. Compared with cancer survivors who did not meet the guidelines for ≥9 MET hours/week−1 of vigorous-intensity exercise, those who met the guidelines had a 51 percent reduction in the risk of any cardiovascular event.

"Vigorous exercise was associated with a lower risk of cardiovascular events in a dose-dependent manner independent of cardiovascular risk profile and treatment in survivors of Hodgkin lymphoma," the authors write.

Two authors disclosed financial ties to pharmaceutical and/or biomedical companies.

Full Text (subscription or payment may be required)

Physician's Briefing